We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Merck Sept 2023 contract said more before end of financial year while Bicycle have regularly been expanding their spending with PYC
This is what oeter said in interins
A significant number of new client contracts are now originating from both scientific conferences (such as EORTC-NCI-AACR & AACR Annual Meeting) as well as more business focused meetings (such as BioEurope) and as such the Company intends to significantly increase its presence at such meetings over the course of this calendar year.
Merck KgaA are also there.
May get some new business from both Bicycle and Merck as we have long standing working relationship with them?
Thanks Debull
Some large names like AstraZeneca there too..also Bicycle are doing
A main presentation on one of the days about their programme of assets
Several complementary options are being pursued simultaneously to build out this new capability and a further update will be provided to the market towards the end of the current financial year. We anticipate that, if successful, this new service line could make a material contribution
I am going to ask about this for the pre submitted questions
Is that 20 lots of 33 shares bought ? 666 in total
Https://info.hansonwade.com/world_adc_london_brochure
Physiomics at the very bottom as a confirmed partner.
Thanks Trench
We're pleased to announce that we're sponsoring #WorldADC 2024! 🎉Meet our experts, Dr. Pete Sargent and Hayley Close, to discover how we can accelerate your #ADC #drugdevelopment journey using cutting-edge PKPD & QSP modelling techniques: https://physiomics.co.uk/world-adc-event-london/ @World_ADC #PYC
Good point KingH
PYC could be profitable if £1mln is hit
The Directors believe the Company will continue to trade in line with market expectations.
Surely this is a 1.5Million pipeline therefore profitable by a few hundred k
Tonl say in March they are confident of achieving £1mln they must be confident of visibility March to early June
Now that the interims are out I expect the new boss to make his mark and start to turn this company around ... All just IMHO ; ... watch this space ... comes to mind
I wish everyone had a crystal ball ....we all be richer ....
Msuk.int,
Of course they will have sales... But, revenue of £374k resulted in the use of £352k cash... They saw nearly £1 out the door for every £1 in turnover. At that rate they will need more funds in the Summer.
Biostatistics service line
The Company was excited to announce its intention to develop a separate consulting service line focused on the delivery of biostatistics projects. Several complementary options are being pursued simultaneously to build out this new capability and a further update will be provided to the market towards the end of the current financial year. We anticipate that, if successful, this new service line could make a material contribution to the Company's revenues and bottom line in the financial year ending 30 June 2025
Not if they are breaking even or better. Time to get some of the pipeline converted. Good update, next 6 months really important in trajectory of the company. Come on Pete.
Why do you say this ? are you anticipating that #pyc will have no sales for the next 298 days ?
Net cash generated from / (used in) operating activities (352)
Cash and cash equivalents of £403k at 31 December 2023
At that rate, they will need more funds by August.
Ahceiving £1mln for 2024 would make a mockery of current market value
PYC should be q much higher market value
As debull says
Losses coming down
Client mix improving
Pipeline growing
Cash equivalents healthy
Meeting market expectations and significantly higher than 2023
Not many companies can say the same
Loss per share is 0.15 and was 0.24. A loss yes, but the loss is getting smaller.
Yes, reassuring.
in line with market expectations,.
The Company's pipeline of potential new business now stands at over £1.5m
The Company's pipeline of potential new business now stands at over £1.5m (not risk weighted and excluding Biostatistics), counting only opportunities where a specific project has been discussed with a client. The Company is working hard to both convert opportunities that have progressed to proposal stage and also to refill the funnel with earlier stage opportunities. A significant number of new client contracts are now originating from both scientific conferences (such as EORTC-NCI-AACR & AACR Annual Meeting) as well as more business focused meetings (such as BioEurope) and as such the Company intends to significantly increase its presence at such meetings over the course of this calendar year
The Directors are pleased that the Company is on track to meet expectations, which, if achieved, would mean a significant increase in total income compared with the financial year ended 30 June 2023
They have shareholder funds at half year of £672k v market cap of £1.8mlm and importantly costs will come down eg new flexible office e
They have RE ITERATES full year guidance (£1mln) so are clearly expecting a good next 3mths
Https://www.physiomics.co.uk/about/team/
Mistry still on webpage?